However, evaluating glucose consumption in AD is made complex by other additional factors, including changes in the expression of glucose transporters (GLUT) (e.g., a reduction of GLUT-3), insulin/insulin-growth-factor 1 axis dysregulation and defects due to the disruption of the neurovascular unit [44,45,46]. This evidence concerns the gene SLC2A1 and Alzheimer disease.